The World Health Organization (WHO) said that it was still conducting its safety review of the AstraZeneca/Oxford Covid-19 vaccine as more European countries have suspended the use of this jab following reports that some recipients developed blood clots and died after being inoculated.
Since March 12, "several countries have suspended the use of AstraZeneca vaccine as a precautionary measure after reports of blood clots in people who had received the vaccine from two batches produced in Europe", WHO Director-General Tedros Adhanom Ghebreyesus said at a press briefing here on Monday.
However, he added that "this does not necessarily mean these events are linked to vaccination, but it's routine practice to investigate them and it shows that the surveillance system works and that effective controls are in place".
He emphasized that the WHO's Global Advisory Committee on Vaccine Safety has been reviewing the available data, is in close contact with the European Medicines Agency (EMA) and will meet on Tuesday.
The European nations that has halted the usage of the vaccine are France Germany, Italy, Spain, Slovenia, Cyprus, Portugal,Austria, Bulgaria, Denmark, Romania, Estonia, Lithuania, Luxembourg, Latvia, the Netherlands, as well as non-EU countries of Norway and Iceland.
Tedros said that "the greatest threat that most countries face now is lack of access to vaccines", as "some of the world's richest countries are buying enough vaccines to immunise their populations several times over", while many other countries have nothing.
The WHO chief continued to call on all countries to work in solidarity to ensure that vaccination begins within the first 100 days of this year.
"No country can simply vaccinate its way out of this pandemic alone. We are all in this together," he said.
--IANS
ksk/
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)